Immunisation Against Streptococcus Pneumoniae
Conditions
Keywords
Post-marketing surveillance, Prescribing Information (PI), Healthy infants and children, Streptococcus pneumoniae, Synflorix™, Sri Lanka
Brief summary
This PMS study aims to collect safety and reactogenicity data of Synflorix™ in healthy infants and children of the local population as per the licensing requirement of the Sri Lankan regulatory authority.
Detailed description
The participating physicians (investigators) will be asked to enrol only those subjects to whom they administer Synflorix™ in the course of their normal clinical practice according to the locally approved Prescribing Information. Since there is lack of clarity regarding the PMS study requirement (both from Regulatory agency and Ethics Committee), it was decided that GSK will submit Local PSURs on a regular basis as desired by Local regulatory agency. The same is communicated to Regulatory agency and if they want something more they are requested to revert back with specific requirements.
Interventions
Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
Sponsors
GlaxoSmithKline
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Weeks to 5 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes that their parent(s)/ LAR(s) can and will comply with the requirements of the protocol should be enrolled in the PMS study. * Infants aged 6 weeks and above and children. * Written, signed or thumb-printed informed consent obtained from the parent(s)/LAR(s) of the child. Where subject's parent(s)/LAR(s) are illiterate, the consent form will be countersigned by an impartial witness. Note: Consent for this PMS study is solely for collection of safety and reactogenicity data and not for vaccination that is per routine practice. Data for demography, medical history and previous vaccination history, and concomitant medication/vaccination will also be collected.
Exclusion criteria
* Subjects with contraindications according to the locally approved PI. * Child in care. * Previous administration of three doses of Synflorix™. * Previous vaccination with a pneumococcal vaccine other than Synflorix™. * Planned administration of another pneumococcal vaccine other than Synflorix™ during the PMS study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of solicited local (any intensity) and general (any intensity and causally related) adverse events (AEs) | During the 4-day follow-up period (Day 0 to Day 3) following any dose of Synflorix™ and overall |
| Occurrence of unsolicited AEs | During the 31-day period (Day 0 to Day 30) following any dose of Synflorix™ and overall |
| Occurrence of Serious Adverse Events (SAEs) | Throughout the PMS study period, starting at Dose 1 (Visit 1) and ending 31 days (Day 0 to Day 30) after the last dose of Synflorix™ for each subject in the PMS study |
Outcome results
None listed